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Letters to the Editor
Sir,
We read with interest the article by Coleman et al reportinc on
prognostic factors at the time of diagnosis of metastatic breast
cancer. The factors which the investigators found are precisely
those which we reported previously (Williams et al. 1986:
Robertson et al. 1992). We are surprised that the authors appear
unaware of this previous work as it has been widely presented in
addition to being published. Blanco and colleagues also reported
similar findings in this very journal in 1991 (Blanco et al. 1991).
The investigators in this case did not use Cox analysis. from
which the 3-values generated mav be used to construct an index
which prospectively places patients in different prognostic groups.
Only bv doing so can the work have any clinical application.
Blanco found that the index which we had derived (Wlliams et al.
1986) and confirmed (Robertson et al. 1992) worked very well in
his population (Blanco et al. personal communication). Having
identified independent factors. wve wonder what is the value ofthis
ifone does not combine them into a clinicallv useful index.
JFR Robertson and RWBlamey; City Hospital. Hucknall Road.
Nottingham NG5 IPB. UK
REFERENCES
Blanco et al (1991 Proenostic factors in recurrence breast cancer relationship to
site ofrecurrence. disease-free interval. female sex steroid receptors. ploid%
and histological malignancv-grading BrJ Cancer 62: 142-146
Robertson JFR. Dixon AC. Nicholson RI. Ellis 10. Elston CW and Blamev RAW
(1992) Confirmation ofa prognostic index for patients vsith metastatic breast
cancer treated by endocrine therapy. Br Cancer Res Treat 22: 221-227
AWilliams MR. Todd JH. Nicholson RI. Elston CUW and Blanesv RW (1986) Survival
paerms in endocrine-trated advanced breast cancer. BrJSure 73: 752
Reply to the letter from Robertson to Blamey
Sir,
We are well aware of the prognostic factors in advanced breast
cancer described by the Nottingham Group and many other centres
around the world. but Robertson and Blamey appear to have
missed the point of our publication. Our series relates specifically
to breast cancer patients with bone as the first site of recurrence
and contains 4-5 times the number of patients with this problem
compared with the references cited by them. Our study investi-
gates factors which may determine the subsequent clinical course
of this specific subgroup and evaluates factors which predict for
disease remaining confined to the skeleton. The aim of the study
was to define patient groups who are mostly likely to develop
skeleton-related events as their dominant clinical problem and.
thus. benefit most from bisphosphonate treatment.
We did use the Cox regression anal sis. but chose not to
construct a prognostic index because the next stage of investiga-
tion is to correlate the exact number of skeleton-related events
with the prognostic subgroups we have defined to determine
whether these are indeed a greater clinical problem in those
patients with bone-only disease and a prolonged survival. Only
then can rational guidelines be made on the selection of patients
for bisphosphonate treatment.
RE Coleman andRDRubens. Department ofClinical Oncology;
The University ofSheffield, Weston Park- Hospital NHS Trust,
Whitham Road, Sheffield S1O 2SJ. UK
Ultraviolet radiation and cutaneous lymphoma
Sir,
Iscovich et al (1998) point to the immunosuppressive effect of
ultraviolet radiation (UV) as a possible factor in the development
of cutaneous lymphoma. However. they overlook the direct anti-
neoplastic effect of UV-B on early stage cutaneous T-cell
lymphoma (CTCL). The effectiveness ofUV-B in the treatment of
early stage CTCL. especially patch-stage mycosis fungoides (MF).
is well documented (Hermann et al. 1995). The sun-protected
regions. for example the bathing-trunk area and the female breasts.
are sites ofpredilection for lesions ofMF. By contrast. the face and
dorsa ofthe hands are relativeely uncommon locations.
The authors use the term cutaneous lymphoma (CL) to include
both MF and non-MF cutaneous lymphomas. They then compare
the incidence of CL in Israel with that reported by Weinstock
and Horm (1988) for the USA. However. the data of Weinstock
and Horm refer specifically only to MF [including the Sezary
svndrome (SS)]. In the registry for CL of the European
Organization for Research and Treatment of Cancer (EORTC)
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